Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pollution, Isotonic Nasal Wash, NSAID Evaluation (PINE)

NCT07925229 is registered in ClinicalTrials.gov with University of British Columbia as lead sponsor.

NCT NCT07925229 Not yet recruiting Phase 4 20 participants (estimated) Started 2026 1 site

Follow this trial by email Email me the PDF

Get the NCT07925229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started December 2026. Interventional study, Phase 4, 20 participants (estimated). Lead sponsor University of British Columbia; Canada. Primary measures: Effects of wood smoke on airway inflammation with Advil and Otrivin: FeNO; Effects of wood smoke on airway inflammation with Advil and Otrivin: Cytokines and Oxylipins and 2 more.

Registry record

As filed in ClinicalTrials.gov.

Title
Pollution, Isotonic Nasal Wash, NSAID Evaluation (PINE)
Lead sponsor
University of British Columbia
Phase
Phase 4
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
December 31, 2029
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them.

this study will evaluate the effects of woodsmoke exposures and advil in healthy adults

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
19 Years
Maximum age
80 Years
Healthy volunteers
Yes
Study type
Interventional
Sites
1
Countries
Canada
Lead sponsor
University of British Columbia

Arms

As registered; 4 arms.

Registered arms
Arm Type Interventions
Filtered Air exposure with Placebo Placebo comparator Filtered Air exposure, Placebo Pill
Show registry wording

Participants will be exposed to high-efficiency particulate air (HEPA) filtered air for 2 hours, and will take a placebo both before, and 3, 10, 22 hours after.

Filtered Air exposure with Advil (Ibuprofen) Experimental Filtered Air exposure, Ibuprofen (Advil 400 mg x 4)
Show registry wording

Participants will be exposed to high-efficiency particulate air (HEPA) filtered air for 2 hours and will take Advil (Ibuprofen 400mg) both before, and 3, 10 and 22 hours after.

Wood Smoke exposure with Placebo Experimental Placebo Pill, Wood Smoke (Lodgepole Pine) exposure
Show registry wording

Participants will be exposed to wood smoke, standardized to 500µg/m3 of PM2.5, for 2 hours and will take a placebo both before, and 3, 10 and 22 hours after.

Wood Smoke exposure with Advil (Ibuprofen) Experimental Ibuprofen (Advil 400 mg x 4), Wood Smoke (Lodgepole Pine) exposure
Show registry wording

Participants will be exposed to wood smoke, standardized to 500µg/m3 of PM2.5, for 2 hours and will take Advil (Ibuprofen 400mg) both before, and 3, 10 and 22 hours after.

Primary endpoints

Registered primary outcome measures; 4 primary.

Registered primary endpoints
Measure Time frame
Effects of wood smoke on airway inflammation with Advil and Otrivin: FeNO Comparison of the different arms over the span of 5 months.
Show registry wording

Measurement of fractional exhaled nitric oxide (FeNO).

Effects of wood smoke on airway inflammation with Advil and Otrivin: Cytokines and Oxylipins Comparison of the different arms over the span of 5 months.
Show registry wording

An inflammation matrix will be generated, including data from nasal inflammatory cytokines and oxylipins, with independent collection from each nostril.

Effects of wood smoke exposure on airflow and resistance in the airways with Advil and Otrivin: PNIF Comparison of the different arms over the span of 5 months.
Show registry wording

Measure nasal patency using peak nasal inspiratory flow (PNIF) analysis.

Effects of wood smoke exposure on airflow and resistance in the airways with Advil and Otrivin: Oscillometry Comparison of the different arms over the span of 5 months.
Show registry wording

Determine small airways function/resistance using oscillometry.

Patents and exclusivity

By drug, as the FDA Orange Book declares its patents.

  • IBUPROFEN 10 Orange Book patentsPatent cliff March 16, 2032 (Orange Book patent)
    • US 11806400; expires March 16, 2032; assignee Cumberland Pharmaceuticals Inc
    • US 9072661; expires March 16, 2032; assignee Cumberland Pharmaceuticals Inc
    • US 9072710; expires March 16, 2032; assignee Cumberland Pharmaceuticals Inc
    • US 9012508; expires September 14, 2030; assignee Cumberland Pharmaceuticals Inc
    • US 8735452; expires September 30, 2029; assignee Cumberland Pharmaceuticals Inc
    • +5 more patents

Lead sponsor's other trials

University of British Columbia, most recent start first.